FDA clears 1st treatment for pancreatic cancer in 30 years, approving Optune Pax to improve survival with chemotherapy.

The FDA has approved a first-of-its-kind portable, noninvasive device that delivers alternating electrical fields for the treatment of locally advanced pancreatic cancer.Optune Pax (Novocure) releases ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

When a cell divides, it performs a feat of microscopic choreography—duplicating its DNA and depositing it into two new cells.

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

Novocure (NASDAQ:NVCR) surged as much as 34% in premarket trading on Thursday after securing U.S. regulatory approval for its wearable therapy designed to treat pancreatic cancer. The U.S. Food and ...

A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G.

The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a ...